Invention Grant
- Patent Title: Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
-
Application No.: US15967452Application Date: 2018-04-30
-
Publication No.: US10702508B2Publication Date: 2020-07-07
- Inventor: Arturo Molina
- Applicant: Aragon Pharmaceuticals, inc.
- Applicant Address: US CA San Diego
- Assignee: Aragon Pharmaceuticals, Inc.
- Current Assignee: Aragon Pharmaceuticals, Inc.
- Current Assignee Address: US CA San Diego
- Agency: BakerHostetler
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; A61P35/00 ; A61K31/4166 ; A61K31/4178 ; A61K31/192 ; A61K31/4365 ; A61K31/496 ; A61K31/427 ; A61K9/00 ; G06Q30/06 ; A61K31/4152 ; A61K31/4155 ; A61K31/426 ; A61K31/00
Abstract:
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
Public/Granted literature
- US20190111036A1 ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Public/Granted day:2019-04-18
Information query
IPC分类:
